MedTrace Logo

Autologous T Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) Patients

NCT00058656 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2006-11-22

No results posted yet for this study

Summary

Patients will have immune cells collected and then expanded outside of the body. Patients will receive an infusion of a large number of expanded immune cells. There will be three dose levels studied. The goal of the study will be to determine the safety as well as potential efficacy of this treatment.

Conditions

Interventions

PROCEDURE

Infusion of Activated & Expanded Autologous T Cells

Sponsors & Collaborators

  • Xcyte Therapies

    lead INDUSTRY

Principal Investigators

  • Mark Frohlich, MD · Xcyte Therapies

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00058656 on ClinicalTrials.gov